Cell analysis solutions company Cytek Biosciences has acquired the cell analysis business of Tonbo Biosciences. The deal includes the acquired business’s portfolio of research reagents, which supports additional applications — cell preparation, molecular immunology/polymerase chain reaction, and cell culture covering application areas across immunology, apoptosis, and immunoprofiling. In a press release, Cytek said that the acquisition of the portfolio will enable it to provide extended flow cytometry capabilities to meet customer needs in protein and cell analysis research. “Tonbo’s reagents will complement Cytek’s cFluor family of proprietary reagents, which represent the culmination of years of full-spectrum cytometry and how fluorophores react together in multicolor panels,” Cytek said. “Adding Tonbo’s reagent offerings to our existing Full-Spectrum Profiling (FSP) platform is yet another example of our commitment to redefining what is possible in flow cytometry and offering a total solution to our users,” said Wenbin Jiang, president and CEO of Cytek. Terms of the deal were not disclosed. Cytek Biosciences, which closed its initial public offering in July, will announce its third-quarter earnings Nov. 8.